Avecho Biotechnology Limited advise that it has received ethics approval for its Phase I clinical trial, that will characterise the absorption profile of cannabidiol (CBD) from its TPM®-enhanced pharmaceutical CBD product in healthy volunteers. Avecho's oral CBD formulation has already been demonstrated to increase the oral bioavailability of CBD in animal models when compared to standard CBD preparations. Increasing the absorption of cannabinoids will support the development of differentiated cannabinoid products on the market, with potential for greater therapeutic potential and/or reduced cost to patients. The Company is already participating in the CAClinics Observational Study (CACOS), Australia's largest running observational study of medicinal cannabis products in patients, to gather real world feedback on how this product will perform for a range of indications that currently utilise medicinal cannabis therapy. The study will measure the safety and absorption profile of the CBD product developed with TPM® and the data will form an integral part of a future TGA submission and drug label. The study will take place at CMAX in Adelaide with 16 healthy volunteers. The study will be a cross-over design comparing the absorption of CBD after consumption of soft-gel capsules at two different doses; 75 mg and 150 mg. These clinical doses were chosen to align with the TGA's down-scheduling of CBD, which has specified that future over-the- counter CBD products must have a maximum daily dose of 150 mg.